Skip to content
Screener

Apogee Therapeutics, Inc. APGE Total Liabilities & Equity

Total Liabilities & Equity at other companies

Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$41.73B+9.2%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$763.27M+198%
AbbVie logo
AbbVieABBV
$136.46B+0.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$329.68M-21.9%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$490.78M+288%

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$10.17B+380%
Enterprise value$9.73B+385%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 7:20 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-215698
Line itemMARCH 31,2026DECEMBER 31,2025
Commitments and contingencies (Note 9)
Stockholders' equity:
Common Stock; $0.00001 par value, 400,000,000 authorized, 75,323,726 issued and 74,882,396 outstanding as of March 31, 2026; 400,000,000 authorized, 69,038,943 issued and 68,401,349 outstanding as of December 31, 202511
Additional paid-in capital1,892,4111,464,561
Accumulated other comprehensive income (loss)(749)1,080
Accumulated deficit(635,870)(561,759)
Total stockholders’ equity1,255,793903,883
Total liabilities and stockholders’ equity$1,293,654$937,134

Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)

FAQ

What is Apogee Therapeutics, Inc.'s total liabilities & equity?
Apogee Therapeutics, Inc. (APGE) reported total liabilities & equity of $1.29B in Q1 2026.
How has Apogee Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
Apogee Therapeutics, Inc.'s total liabilities & equity increased by 81.1% year-over-year, from $714.16M to $1.29B.
What is the long-term trend for Apogee Therapeutics, Inc.'s total liabilities & equity?
Over 3 years (2022 to 2025), Apogee Therapeutics, Inc.'s total liabilities & equity has grown at a 83.3% compound annual growth rate (CAGR), from $152.06M to $937.13M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Apogee Therapeutics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude